The goal of the Harvard/MIT MD-PhD Program is to provide our students with a world-class educational experience that embraces an integration of compassionate medical care and breakthrough research to drive biomedical discovery and translation. We are laser-focused on creating an intellectually dynamic and nurturing community that enables our students to flourish, both personally and professionally, throughout their award period. This year?s Harvard Medical School curriculum revision has provided the MD-PhD program with an unprecedented opportunity to optimize the integration of MD and PhD education for our students, who benefit from two tracks, namely Pathways and Health, Sciences, and Technology (HST). Pathways features a large and diverse class whose backgrounds run the gamut of liberal arts education. The Pathways curriculum now starts with a 14 month intensive introduction to the essentials of medical education with prompt entry to the wards by October of Year 2. The HST program has a smaller class that emphasizes the science behind the medicine, focusing on mechanism, quantitation, and innovation. HST class work runs through March of Year 2, followed by the transition to the wards. Thus, all MD-PhD students now experience clinical responsibility prior to initiating their PhD studies, providing clinical insight that can influence their research direction and catalyze early career planning. This upfront clinical credit affords a new level of scheduling flexibility for re-entry to Year 3 of medical school after PhD completion, which should benefit the overall time-to-degrees. Our students have limitless options for PhD training in the basic, engineering, and social sciences across the campuses of Harvard Medical School, MIT, and all affiliated Boston hospitals and research institutes. Upon return from graduate school, the hospital experiences of Pathways and HST students are balanced with educational components that emphasize an intimate linkage between pathophysiology and patient relevance. Importantly, the MD-PhD program faculty and staff provide the academic, social, and administrative glue that brings our robust community of 181 students together. Led by Faculty Director, Loren Walensky, MD, PhD, and Administrative Director, Amy Cohen, our program is composed of key organizational components including a Board of Overseers, Faculty Leadership Council, Subcommittees on Academic Advising, Admissions, and Social Sciences, a Student Steering Committee, and Program Office Staff. Academic paracurricular offerings include our summer zero course, noon clinical case conferences, MD-PhD grand grounds, a clinical preceptorship program, transition bootcamps, meet- the-investigator series, and alumni career development mixers. To provide for a rich social environment, we also offer a summer barbecue, weekend long retreat on Cape Cod, a big sib program, ?dinners for 8?, MD-PhD breakfasts and happy hours, and a series of special events at faculty member homes. Under new leadership since 2013, the MD-PhD program has implemented a battery of programmatic changes designed to maximize the educational impact of MD-PhD training at Harvard and MIT.
The mission of the MD-PhD Program at Harvard and MIT is to train the next-generation of physician-scientist leaders who will intertwine premier clinical care and leading edge scientific investigation to deliver on the promise of new biomedical solutions to alleviate human suffering. By harnessing the academic, clinical, and research environments of Harvard Medical School, the Massachusetts Institute of Technology, and all affiliated Boston hospitals and research institutes, we aim to provide our students with unparalleled depth and breadth of clinical and research educational opportunities balanced by a profoundly caring and invested community of student colleagues and faculty mentors. Under new leadership since 2013, the program has undergone a comprehensive review of operations to both reinforce what works and institute a battery of educational, social, and administrative changes to make the Harvard/MIT training experience that much better, now and into the future.
|Wiens, Jenna; Snyder, Graham M; Finlayson, Samuel et al. (2018) Potential Adverse Effects of Broad-Spectrum Antimicrobial Exposure in the Intensive Care Unit. Open Forum Infect Dis 5:ofx270|
|Kwan, Tanya T; Bardia, Aditya; Spring, Laura M et al. (2018) A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discov 8:1286-1299|
|Knouse, Kristin A; Lopez, Kristina E; Bachofner, Marc et al. (2018) Chromosome Segregation Fidelity in Epithelia Requires Tissue Architecture. Cell 175:200-211.e13|
|Loh, Po-Ru; Genovese, Giulio; Handsaker, Robert E et al. (2018) Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature 559:350-355|
|Katwa, Umakanth; D'Gama, Alissa M; Qualls, Anita E et al. (2018) Atypical presentations associated with non-polyalanine repeat PHOX2B mutations. Am J Med Genet A 176:1627-1631|
|Hong, Xin; Sullivan, Ryan J; Kalinich, Mark et al. (2018) Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A 115:2467-2472|
|McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25|
|Steinhorn, Benjamin; Sorrentino, Andrea; Badole, Sachin et al. (2018) Chemogenetic generation of hydrogen peroxide in the heart induces severe cardiac dysfunction. Nat Commun 9:4044|
|Giacomelli, Andrew O; Yang, Xiaoping; Lintner, Robert E et al. (2018) Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet 50:1381-1387|
|Gurry, Thomas; HST Microbiome Consortium*; Gibbons, Sean M et al. (2018) Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort. Sci Rep 8:12699|
Showing the most recent 10 out of 867 publications